# Oramed Pharmaceuticals Inc.: Form 10-Q for the period ended Jun 30, 2022

- Company: [Oramed Pharmaceuticals Inc.](/companies/ormp.md) (CIK 1176309)
- Form: 10-Q
- Filed: 2022-08-10
- Accepted by EDGAR: Aug 10, 2022, 16:45 ET
- Period: 2022-06-30
- Accession: 0001213900-22-046399
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1176309/000121390022046399/f10q0622_oramedpharm.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1176309/000121390022046399/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-04-01 to 2022-06-30 | $674.0k | us-gaap:Revenues |
| Revenue | 6 months, 2022-01-01 to 2022-06-30 | $1.3m | us-gaap:Revenues |
| Research and development | 3 months, 2022-04-01 to 2022-06-30 | $9.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2022-01-01 to 2022-06-30 | $15.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2022-04-01 to 2022-06-30 | −$11.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2022-01-01 to 2022-06-30 | −$22.7m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2022-04-01 to 2022-06-30 | −$11.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2022-01-01 to 2022-06-30 | −$21.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-04-01 to 2022-06-30 | $0.27 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2022-01-01 to 2022-06-30 | $0.54 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-04-01 to 2022-06-30 | $0.27 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2022-01-01 to 2022-06-30 | $0.54 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-04-01 to 2022-06-30 | 38,795,318 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2022-01-01 to 2022-06-30 | 38,732,636 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2022-01-01 to 2022-06-30 | −$17.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2022-01-01 to 2022-06-30 | $67.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | at 2022-06-30 | $134.9m | us-gaap:AssetsCurrent |
| Total assets | at 2022-06-30 | $162.3m | us-gaap:Assets |
| Current liabilities | at 2022-06-30 | $6.4m | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2022-06-30 | $7.3m | us-gaap:LongTermDebt |
| Shareholders' equity | at 2022-06-30 | $153.7m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1176309/000121390022046399/f10q0622_oramedpharm.htm

Filed Aug 10, 2022.
Source: SEC EDGAR, the filing index for accession 0001213900-22-046399. Last ingested by Listed: Nov 15, 2026, 04:14 ET. No prices; not investment advice.
